|
Contents
|
|
|
|
Glioblastoma
|
|
|
|
|
Dirk Vordermark, Klemens Ruprecht, Peter Rieckmann,
Wolfgang Roggendorf, Giles H Vince, Monika Warmuth-Metz, Oliver Kölbl, and
Michael Flentje
Glioblastoma multiforme with oligodendroglial component (GBMO): favorable
outcome after post-operative radiotherapy and chemotherapy with nimustine (ACNU)
and teniposide (VM26)
BMC Cancer. 2006 Oct
18;6:247
.JPG)
Abstract
| .png)
Full
Text | .png)
Reprint
|
|
|
Glas M, Hundsberger T, Stuplich M, Wiewrodt D,
Kurzwelly D, Nguyen-Huu B, Rasch K, Herrlinger U
Nimustine (ACNU) Plus Teniposide (VM26) in Recurrent Glioblastoma
Oncology. 2009 Feb 13;76(3):184-189. [Epub ahead of print]
Abstract
|
|
|
Gliomas
|
|
|
|
Lynn G. Feun, Angela Marini,
Howard Landy, Arnold Markoe, Deborah Heros, Carlos Robles,
Cristina Herrera and Niramol Savaraj
Clinical trial of CPT-11 and VM-26/VP-16 for patients with recurrent
malignant brain tumors
J Neurooncol. 2006 Oct 19; [Epub
ahead of print]
Abstract
|
|
The
Neuro-Oncology Working Group Of The German Cancer Society
Neuro-oncology
working group 01 trial of nimustine plus teniposide versus nimustine plus
cytarabine chemotherapy in addition to involved-field radiotherapy in the
first-line treatment of malignant glioma
J Clin Oncol. 2003 Sep 1;21(17):3276-84 (PDF Full Text)
|
|
|
Oligodendroglioma
|
|
|
|
A. A. Brandes, U. Basso, F. Vastola, A. Tosoni, L. M. Pasetto, A. Jirillo,
S. Lonardi, M. K. Paris, H. Koussis, S. Monfardini and M. Ermani
Carboplatin and teniposide as third-line chemotherapy in patients with recurrent
oligodendroglioma or oligoastrocytoma: a phase II study
Annals
of Oncology 14:1727-1731, December 2003
|
|
